Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
RNA interference (RNAi) is a universal and evolutionarily conserved phenomenon of post-transcriptional gene silencing by means of sequence-specific mRNA degradation, triggered by small double-stranded RNAs. Because this mechanism can be efficiently induced in vivo by expressing target-complementary short hairpin RNA (shRNA) from non-viral and viral vectors, RNAi is attractive for functional genomics and human therapeutics. Here we systematically investigate the long-term effects of sustained high-level shRNA expression in livers of adult mice. Robust shRNA expression in all the hepatocytes after intravenous infusion was achieved with an optimized shRNA delivery vector based on duplex-DNA-containing adeno-associated virus type 8 (AAV8). An evaluation of 49 distinct AAV/shRNA vectors, unique in length and sequence and directed against six targets, showed that 36 resulted in dose-dependent liver injury, with 23 ultimately causing death. Morbidity was associated with the downregulation of liver-derived microRNAs (miRNAs), indicating possible competition of the latter with shRNAs for limiting cellular factors required for the processing of various small RNAs. In vitro and in vivo shRNA transfection studies implied that one such factor, shared by the shRNA/miRNA pathways and readily saturated, is the nuclear karyopherin exportin-5. Our findings have fundamental consequences for future RNAi-based strategies in animals and humans, because controlling intracellular shRNA expression le…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cellular toxicity can, for example, be observed in rAAV shRNA overexpression studies in which ubiquitous promoters were used that caused saturation of cellular miRNA pathways [88].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [88]
In the citing paper
“However, the relatively large size, the requirement that the transcript starts with a G or A, the sometimes too active transcription, and the sensitivity to specific cellular profiles make the human U6 promoter a less versatile promoter [88,131,132].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [88]
In the citing paper
“Consistent with this possibility, when multiple miRNAs are packaged within a single construct, they may compete for processing by the cellular miRNA biogenesis machinery, leading to reduced efficiency in individual miRNA maturation and function 44,45 .”
From rAAV-mediated Multi-miRNA Delivery Targeting MAPK Pathway Suppresses Laser-induced Choroidal Neovascularization in Mice (2026) · cites this paper as [44]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,538
Identification of tissue-specific microRNAs from mouse
Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00809-6 · Cited by 3,355
Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs
Yi, R., Qin, Y., Macara, I. G., & Cullen, B. R. (2003) · Genes & Development · doi:10.1101/gad.1158803 · Cited by 3,010
Nuclear Export of MicroRNA Precursors
Lund, E., Güttinger, S., Calado, A., Dahlberg, J. E., & Kutay, U. (2004) · Science · doi:10.1126/science.1090599 · Cited by 2,714
Mechanisms of gene silencing by double-stranded RNA
Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,539
Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA
Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., & Sarnow, P. (2005) · Science · doi:10.1126/science.1113329 · Cited by 2,521
Self-citationExportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs
BOHNSACK, M. T., CZAPLINSKI, K., & GÖRLICH, D. (2004) · RNA · doi:10.1261/rna.5167604 · Cited by 1,433
Cited by
Items 501–600 of 1,001
Zhao, X., Fjose, A., Larsen, N., Helvik, J. V., & Drivenes, Ø. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06371.x · Cited by 54
In silico selection of active siRNA
Patzel, V. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.015 · Cited by 59
Baldassarre, A., Paolini, A., Bruno, S. P., Felli, C., Tozzi, A. E., & Masotti, A. (2020) · Epigenomics · doi:10.2217/epi-2020-0162 · Cited by 50
Specificity of oligonucleotide gene therapy (OGT) agents
Nedorezova, D. D., Dubovichenko, M. V., Belyaeva, E. P., Grigorieva, E. D., Peresadina, A. V., & Kolpashchikov, D. M. (2022) · Theranostics · doi:10.7150/thno.77830 · Cited by 54
“The later affects Exportin-5 [70-72] and the RISC complex (Figure 4) [73,74].”
BackgroundEngineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression
Kabadi, A. M., & Gersbach, C. A. (2014) · Methods · doi:10.1016/j.ymeth.2014.06.014 · Cited by 46
“Although RNAi is currently the most widely used gene silencing technology, it can be challenging to find specific target sequences and RNAi can interfere with endogenous microRNA processing pathways (85).”
BackgroundChiosea, S. I., Barnes, E. L., Lai, S. Y., Egloff, A. M., Sargent, R. L., Hunt, J. L., & Seethala, R. R. (2008) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-007-0574-5 · Cited by 53
“Furthermore, some adverse effects appear to be caused by competition of exogenous siRNAs with the endogenous miR for proteins of miR machinery (e.g., Exportin-5) [ 12 ].”
BackgroundStem cell-based anti-HIV gene therapy
Kitchen, S. G., Shimizu, S., & An, D. S. (2011) · Virology · doi:10.1016/j.virol.2010.12.039 · Cited by 56
“This cytotoxicity could be caused by saturation of endogenous micro RNA biogenesis (Grimm et al., 2006; Grimm et al., 2010).”
BackgroundWei, J., Jones, J. J., Kang, J., Card, A., Krimm, M., Hancock, P. J., Pei, Y., Ason, B. L., Payson, E., Dubinina, N., et al. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.070409 · Cited by 54
“In particular, there is a concern that the use of therapeutic siRNAs will be limited to life-threatening diseases because siRNAs have the potential to saturate RISC machinery, resulting in toxicity (Grimm et al., 2006).”
BackgroundMicroRNA Signatures in Neurological Disorders
Shafi, G., Aliya, N., & Munshi, A. (2010) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100009902 · Cited by 49
A large‐scale functional screen identifies Nova1 and Ncoa3 as regulators of neuronal miRNA function
Störchel, P. H., Thümmler, J., Siegel, G., Aksoy‐Aksel, A., Zampa, F., Sumer, S., & Schratt, G. M. (2015) · The EMBO Journal · doi:10.15252/embj.201490643 · Cited by 54
“In addition to its extensively characterized function in transcription, two reports suggest a post-transcriptional cytosolic function of Ncoa3 in non-neuronal cells (Yu et al , 2007; Long et al , 2010) (Grimm et al , 2006; Borner et al , 2013).”
Generation of Hairpin-Based RNAi Vectors for Biological and Therapeutic Application
Boudreau, R. L., & Davidson, B. L. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-386509-0.00014-4 · Cited by 55
MicroRNA-Based Therapy in Animal Models of Selected Gastrointestinal Cancers
Merhautova, J., Demlova, R., & Slaby, O. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00329 · Cited by 47
“As Grimm et al. studied almost 50 distinct shRNAs, they assume that the effect was not sequence related (Grimm et al., 2006).”
BackgroundFuture of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond
Valdmanis, P. N., & Kay, M. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.171 · Cited by 58
“Other concerns of the CRISPR/Cas9 system include the widespread use of the U6 Pol-III promoter to drive sgRNAs; this promoter can lead to toxicity when used to express shRNAs at high levels.(20,37) Situations that preclude the efficacy of this approach should be reported to ensure that the field is aware of scenarios…”
Self-citationAdvances in MicroRNAs: Implications for Gene Therapists
Marquez, R. T., & McCaffrey, A. P. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.147 · Cited by 56
RNA interference and antiviral therapy
Ma, Y., Chan, C.-Y., & He, M.-L. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i39.5169 · Cited by 51
Chen, L., McKenna, J. T., Bolortuya, Y., Winston, S. H., Thakkar, M. M., Basheer, R., Brown, R. E., & McCarley, R. W. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07401.x · Cited by 51
“A vector-based RNAi could be even more effective; however, it has been reported that in vivo RNAi via viral vectors causes toxic effects in blood, liver, lung and brain (Swoap et al., 2004; An et al., 2006; Grimm et al., 2006; Chiosea et al., 2007; McBride et al., 2008).”
BackgroundLiang, X.-H., Hart, C. E., & Crooke, S. T. (2013) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2013.01.011 · Cited by 48
Gene-Based Therapy for Alpha-1 Antitrypsin Deficiency
Mueller, C., & Flotte, T. R. (2013) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2013.764978 · Cited by 49
“Concerns arose about the safety of shRNA overexpression in the liver (24).”
BackgroundBortolanza, S., Nonis, A., Sanvito, F., Maciotta, S., Sitia, G., Wei, J., Torrente, Y., Serio, C. D., Chamberlain, J. R., & Gabellini, D. (2011) · Molecular Therapy · doi:10.1038/mt.2011.153 · Cited by 57
Delivering a disease-modifying treatment for Huntington's disease
Godinho, B. M. D. C., Malhotra, M., O’Driscoll, C. M., & Cryan, J. F. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.011 · Cited by 54
Cunha, C. S. E., Nyboer, B., Heiß, K., Sanches‐Vaz, M., Fontinha, D., Wiedtke, E., Grimm, D., Przyborski, J. M., Mota, M. M., Prudêncio, M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606419114 · Cited by 58
“rAAV vector particles were purified by cesium chloride density gradient centrifugation (69).”
MethodSelf-citationRNA interference: An emerging generation of biologicals
Shrivastava, N., & Srivastava, A. (2008) · Biotechnology Journal · doi:10.1002/biot.200700215 · Cited by 55
“Moreover, as they enter the RNAi pathway later, siRNAs are less likely to interfere with gene regulation by endogenous miRNAs [64].”
BackgroundsiRNA and the lung: research tool or therapeutic drug?
de Fougerolles, A., & Novobrantseva, T. I. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.04.005 · Cited by 49
“In addition, because they enter the RNAi pathway later, siRNAs are less likely to interfere with gene regulation by endogenous miRNA [4,5].”
Gene Therapy in Orthopaedics: Progress and Challenges in Pre-Clinical Development and Translation
Levings, R. W., Palmer, G. D., Levings, P. P., Dacanay, E. A., Evans, C. H., & Ghivizzani, S. C. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.901317 · Cited by 52
“Since the use of RNAi in vivo requires high vector doses, overexpression of RNAi gene products in a sub-population of cells is an inevitable consequence, and brings the risk of patient morbidity from prolonged off-target gene silencing (Grimm et al., 2006).”
BackgroundModeling oncogene addiction using RNA interference
Rothenberg, S. M., Engelman, J. A., Le, S., Riese, D. J., Haber, D. A., & Settleman, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803217105 · Cited by 47
“Confounding effects of RNAi approaches include induction of an interferon response (10), unexpected ‘‘off-target’’ knockdown of unrelated mRNAs (11) or saturation of endogenous microRNA pathways (12).”
BackgroundAn engineered U1 small nuclear RNA rescues splicing‐defective coagulation F7 gene expression in mice
Balestra, D., Faella, A., Margaritis, P., Cavallari, N., Pagani, F., Bernardi, F., Arruda, V. R., & Pinotti, M. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12471 · Cited by 49
Kim, S.-M., Lee, K., Lee, S. J., Ko, Y.-J., Lee, H.-S., Kweon, C.-H., Kim, H.-S., & Park, J.-H. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2010.06.004 · Cited by 48
Liang, M., Kamata, M., Chen, K. N., Pariente, N., An, D. S., & Chen, I. S. Y. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1440 · Cited by 48
Gene therapy for alpha-1 antitrypsin deficiency
Flotte, T. R., & Mueller, C. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr156 · Cited by 48
“Despite the fact that no liver toxicity was observed in these studies, the use of shRNA has been shown to have toxicity both in the liver and in the brain in two other studies (21,23).”
Insight into miRNAs related with glucometabolic disorder
Zhang, B., Shen, C., Zhu, B.-W., An, H., Zheng, B. J., Xu, S., Sun, J., Sun, P.-C., Zhang, W., Wang, J., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.123 · Cited by 49
Competition between Small RNAs: A Quantitative View
Loinger, A., Shemla, Y., Simon, I., Margalit, H., & Biham, O. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2012.01.058 · Cited by 51
“Moreover, a link between the two classes of small RNAs was found, as saturation of the endogenous RNAi machinery using siRNAs resulted in dysregulation of endogenous miRNA function (12,13).”
BackgroundOptimization and characterization of tRNA-shRNA expression constructs
Scherer, L. J., Frank, R., & Rossi, J. J. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm103 · Cited by 49
“components of the endogenous RNAi machinery and perhaps increased off-targeting (8,9).”
BackgroundCorrection: An RNAi-Based Approach to Down-Regulate a Gene Family In Vivo
Kim, J., Badaloni, A., Willert, T., Zimber‐Strobl, U., hn, R. K. ⁄., Wurst, W., & Kieslinger, M. (2013) · PLoS ONE · doi:10.1371/annotation/c8b2e360-b78a-4c2f-a1a3-c53325f18211 · Cited by 48
Optimal delivery of RNA interference by viral vectors for cancer therapy
Wong, B., Birtch, R., Rezaei, R., Jamieson, T. R., Crupi, M. J. F., Diallo, J., & Ilkow, C. S. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.09.012 · Cited by 49
Borel, F., van Logtenstein, R., Koornneef, A., Maczuga, P., Ritsema, T., Petry, H., van Deventer, S. J. H., Jansen, P. L. M., & Konstantinova, P. S. (2011) · PubMed · Cited by 47
Yang, X., Haurigot, V., Zhou, S., Luo, G. G., & Couto, L. B. (2010) · Hepatology · doi:10.1002/hep.23908 · Cited by 52
“Although adeno-associated virus (AAV) and lentivirus vectors themselves appear to be safe, robust and sustained expression of RNAi effectors from AAV vectors in the form of shRNAs resulted in serious toxicity in both mouse liver(11) and brain,(12,13) and in some cases fatalities occurred.(11) Toxicity correlated with…”
A universal system to select gene-modified hepatocytes in vivo
Nygaard, S. C., Barzel, A., Haft, A., Major, A. M., Finegold, M. J., Kay, M. A., & Grompe, M. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8166 · Cited by 48
Self-citationAl-Ghezi, Z. Z., Singh, N. P., Mehrpouya‐Bahrami, P., Busbee, P. B., Nagarkatti, M., & Nagarkatti, P. S. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02349 · Cited by 59
Multiplexing Seven miRNA-Based shRNAs to Suppress HIV Replication
Choi, J.-G., Bharaj, P., Abraham, S., Ma, H., Yi, G., Ye, C., Dang, Y., Manjunath, N., Wu, H., & Shankar, P. (2014) · Molecular Therapy · doi:10.1038/mt.2014.205 · Cited by 53
Subramanya, S., Kim, S. S., Manjunath, N., & Shankar, P. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903448158 · Cited by 55
“In mice, severe liver toxicity and fatality were reported within two weeks of shRNA treatment, which could be attributed to the saturation of the miRNA pathway by overexpressed shRNA [124].”
BackgroundYang, Y.-S., Kim, J., Xie, J., Chaugule, S. R., Lin, C., Ma, H., Hsiao, E. C., Hong, J., Chun, H., Shore, E. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33956-9 · Cited by 51
Manfredsson, F., Okun, M., & Mandel, R. (2009) · Current Gene Therapy · doi:10.2174/156652309789753400 · Cited by 50
“Results from preclinical studies utilizing knock-down strategies, however, have been confounding, and safety aspects of these approaches remain unresolved [5-7].”
BackgroundMicroRNAs in Neurocognitive Dysfunctions: New Molecular Targets for Pharmacological Treatments?
Nadim, W., Simion, V., Benedetti, H., Pichon, C., Baril, P., & Morisset-Lopez, S. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666160709001441 · Cited by 47
Kim, K., Seo, Y., Kim, E., Lee, S.-Y., Kwon, J., Ko, J.-J., & Lee, K. (2016) · Open Biology · doi:10.1098/rsob.160181 · Cited by 49
Askou, A. L., Alsing, S., Holmgaard, A., Bek, T., & Corydon, T. J. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13407 · Cited by 48
“However, concern has been raised whether the high shRNA potency due to high levels of shRNA molecules being expressed in the cell interferes with the endogenous housekeeping miRNA biogenesis (Grimm et al. 2006; Ehlert et al. 2010; Martin et al. 2011).”
BackgroundSampath, P., Periyasamy, K. M., Ranganathan, U. D., & Bethunaickan, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.667206 · Cited by 49
Orlans, H. O., McClements, M. E., Barnard, A. R., de la Cámara, C. M.-F., & MacLaren, R. E. (2021) · Nature Communications · doi:10.1038/s41467-021-25204-3 · Cited by 47
Eekels, J. J. M., Pasternak, A. O., Schut, A. M., Geerts, D., Jeeninga, R. E., & Berkhout, B. (2011) · Gene Therapy · doi:10.1038/gt.2011.191 · Cited by 57
Jung, H. S., Erkin, Ö. C., Kwon, M. J., Kim, S. H., Jung, J. I., Oh, Y., Her, S., Ju, W., Choi, Y., Song, S. Y., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26197 · Cited by 46
Dissen, G. A., Lomniczi, A., Neff, T. L., Hobbs, T. R., Kohama, S. G., Kroenke, C. D., Galimi, F., & Ojeda, S. R. (2009) · Methods · doi:10.1016/j.ymeth.2009.06.004 · Cited by 49
MicroRNAs in Brain Metastases: Potential Role as Diagnostics and Therapeutics
Alsidawi, S., Malek, E., & Driscoll, J. J. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150610508 · Cited by 48
“Toxicities associated with miRNA therapeutics are not limited to the delivery system since studies have shown that oversaturating small RNA pathways can be lethal [113].”
BackgroundHussain, M. S., Moglad, E. H. O., Afzal, M., Gupta, G., Almalki, W. H., Kazmi, I. A., Alzarea, S. I., Kukreti, N., Gupta, S., Kumar, D., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155303 · Cited by 46
RNAi in Pest Control: Critical Factors Affecting dsRNA Efficacy
Mendoza-Alatorre, M., Julian-Chávez, B., Solano-Ornelas, S., Siqueiros-Cendón, T., Torres‐Castillo, J. A., Sinagawa‐García, S. R., Abraham‐Juárez, M. J., González-Barriga, C. D., Rascón-Cruz, Q., Siañez-Estrada, L. I., et al. (2025) · Insects · doi:10.3390/insects16070737 · Cited by 49
“Moreover, high levels of dsRNA may saturate the RNAi machinery, interfering with normal gene regulation [110,111].”
Gordeladze, J. O., Reseland, J. E., Duroux-Richard, I., Apparailly, F., & Jørgensen, C. (2010) · ILAR Journal · doi:10.1093/ilar.51.1.42 · Cited by 48
“All these approaches will, however, have to deal with toxicity issues due to vector and/or transgenic immunogenicity, as well as the risk of oversaturating endogenous pathways (Grimm et al. 2006).”
BackgroundFeng, Y., Nie, L., Thakur, M. D., Su, Q., Chi, Z., Zhao, Y., & Longmore, G. D. (2010) · Genomics Proteomics & Bioinformatics · doi:10.1016/s1672-0229(10)60025-3 · Cited by 47
Future Challenges for Microsomal Transport Protein Inhibitors
Wierzbicki, A. S., Hardman, T. C., & Prince, W. (2009) · Current Vascular Pharmacology · doi:10.2174/157016109788340703 · Cited by 46
“Furthermore, a recent report in mice cautions that safe and effective RNA-based gene therapies depend on a thorough understanding of the endogenous molecular mechanisms involved [93, 94].”
BackgroundOncomirs: From Tumor Biology to Molecularly Targeted Anticancer Strategies
Mocellin, S., Pasquali, S., & Pilati, P. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709787001802 · Cited by 45
“miRNA mimics from adeno-associated viral vectors in mice could saturate the miRNA pathway and cause an otherwise unexpected severe liver toxicity [104].”
BackgroundPatil, A., Manzano, M., & Gottwein, E. (2018) · Blood · doi:10.1182/blood-2018-01-828418 · Cited by 43
Low-level shRNA Cytotoxicity Can Contribute to MYC-induced Hepatocellular Carcinoma in Adult Mice
Beer, S., Bellovin, D. I., Lee, J. S., Komatsubara, K. M., Wang, L. S., Koh, H., Börner, K., Storm, T. A., Davis, C. R., Kay, M. A., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.222 · Cited by 51
Self-citationThe role of microRNAs in synaptic development and function
Corbin, R., Olsson-Carter, K., & Slack, F. (2009) · BMB Reports · doi:10.5483/bmbrep.2009.42.3.131 · Cited by 43
“that are difficult to interpret or that confound further analysis, as was observed in (30).”
BackgroundAdverse effects induced by short hairpin RNA expression in porcine fetal fibroblasts
Stewart, C. K., Li, J., & Golovan, S. P. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.03.041 · Cited by 45
“Recently it was shown that high level of shRNA expression for 36 out of 49 construct against six different targets in mouse liver interfered with endogenous miRNA pathway resulting in liver toxicity and in some cases in animal death [28].”
BackgroundSilencing of Parkinson's disease-associated genes with artificial mirtron mimics of miR-1224
Sibley, C. R., Seow, Y., Curtis, H., Weinberg, M. S., & Wood, M. J. A. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks712 · Cited by 45
“The dependence on splicing rather than Drosha processing for pre-miRNA hairpin formation implies that mirtrons would be less dependent on the canonical miRNA biogenesis pathway, which previous research has shown to be capable of saturation (9,10,17).”
BackgroundInfluentialA microRNA embedded AAV alpha-synuclein gene silencing vector for dopaminergic neurons
Han, Y. S., Khodr, C. E., Sapru, M. K., Pedapati, J., & Bohn, M. C. (2011) · Brain Research · doi:10.1016/j.brainres.2011.02.041 · Cited by 46
Wang, Q., Wang, H., Yan, H., Tian, H., Wang, Y., Yu, W., Dai, Z., Chen, P., Liu, Z., Tang, R., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn3333 · Cited by 48
“However, introduction of exogenous artificial miRNAs is associated with multiple risks, such as saturation of the RNA processing machinery and off-target effects (19, 20).”
BackgroundCharacterization of a potent non-cytotoxic shRNA directed to the HIV-1 co-receptor CCR5
Shimizu, S., Kamata, M., Kittipongdaja, P., Chen, K. N., Kim, S., Pang, S., Boyer, J., Qin, F. X.-F., An, D. S., & Chen, I. S. Y. (2009) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-7-8 · Cited by 47
Zhang, J., He, Q., Zhang, C., Chen, X., Chen, X.-M., Dong, Z., Li, N., Kuang, X.-X., Cao, M.-Y., Lu, C., et al. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.01.017 · Cited by 44
Dua, P., Yoo, J. W., Kim, S., & Lee, D.-K. (2011) · Molecular Therapy · doi:10.1038/mt.2011.109 · Cited by 49
Designing Ago2-specific siRNA/shRNA to Avoid Competition with Endogenous miRNAs
Ma, H., Zhang, J., & Wu, H. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.27 · Cited by 50
Expression determinants of mammalian argonaute proteins in mediating gene silencing
Valdmanis, P. N., Gu, S., Schüermann, N., Sethupathy, P., Grimm, D., & Kay, M. A. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr1274 · Cited by 43
“Our laboratory has been interested in maintaining high levels of argonaute expression to prevent saturation of RNAi components which can cause lethality in mice (33).”
BackgroundSelf-citationNanoparticle mediated RNA delivery for wound healing
Kolanthai, E., Fu, Y., Kumar, U., Babu, B., Venkatesan, A. K., Liechty, K. W., & Seal, S. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1741 · Cited by 51
New technology for an old favorite: lentiviral transgenesis and RNAi in rats
Dann, C. T. (2007) · Transgenic Research · doi:10.1007/s11248-007-9121-z · Cited by 45
“Three types of effects have been noted: global down-regulation of translation due to activation of an interferon response, toxicity due to oversaturation of the endogenous miRNA pathway, and specific knock-down of unintended target genes (Bridge et al. 2003; Cao et al. 2005; Grimm et al. 2006; Jackson et al. 2003).”
BackgroundInfluentialNanoparticles for human liver-specific drug and gene delivery systems:in vitroandin vivoadvances
Kasuya, T., & Kuroda, S. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240802622096 · Cited by 44
“Overexpression of some shRNAs in mice livers by the adeno-associated virus was found to kill the mice by oversaturation of endogenous small RNA pathways [36] .”
BackgroundA New Version of Grain-128 with Authentication
Ågren, M., Hell, M., Johansson, T., & Meier, W. (2011) · Lund University Publications (Lund University) · Cited by 47
Designing small multiple-target artificial RNAs
Guire, V. D., Caron, M., Scott, N., Ménard, C., Gaumont‐Leclerc, M., Chartrand, P., Major, F., & Ferbeyre, G. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq354 · Cited by 48
Ambardekar, V. V., Han, H.-Y., Varney, M. L., Vinogradov, S. V., Singh, R. K., & Vetro, J. A. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.10.019 · Cited by 46
“Although pDNA has the potential to deliver higher and more sustained dosages of siRNA, unpredictable and subsequently toxic dosages in vivo have been reported [10].”
Lmo Genes Regulate Behavioral Responses to Ethanol in Drosophila melanogaster and the Mouse
Lasek, A. W., Giorgetti, F., Berger, K. H., Tayor, S., & Heberlein, U. (2011) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2011.01506.x · Cited by 43
“This may be due to silencing at the lentiviral integration site, perhaps due to toxicity from high shRNA expression (Cao et al., 2005; Grimm et al., 2006).”
Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic
Miniarikova, J., Evers, M. M., & Konstantinova, P. S. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.002 · Cited by 49
“There are cases showing that overexpression of shRNAs and miRNAs can cause toxicity and off-target activity caused by saturation of the RNAi machinery related to cellular processing of therapeutic precursors or resulting from miRNA target sequence similarity with other genes.(63,64,162) In general, miRNA-induced gene…”
BackgroundXPO5 promotes primary miRNA processing independently of RanGTP
Wang, J., Lee, J. E., Riemondy, K. A., Yu, Y., Marquez, S. M., Lai, E. C., & Yi, R. (2020) · Nature Communications · doi:10.1038/s41467-020-15598-x · Cited by 49
Nucleic Acids-Based Therapeutics in the Battle Against Pathogenic Viruses
Haasnoot, J., & Berkhout, B. (2008) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-79086-0_9 · Cited by 43
“In extreme cases, such side effects can have severe consequences, as illustrated by the mice that died after treatment with an AAV vector for overexpression of shRNAs in the liver (Grimm et al. 2006).”
BackgroundRecent advances in α-1-antitrypsin deficiency-related lung disease
Brebner, J., & Stockley, R. A. (2013) · Expert Review of Respiratory Medicine · doi:10.1586/ers.13.20 · Cited by 49
Mir-434-5p mediates skin whitening and lightening
Lin, S.-L., Wu, Chen, Chang, & Lin, S.-L. (2008) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s4181 · Cited by 43
“Since Grimm et al have reported that high concentrated siRNA/shRNA can over-saturate the cellular miRNA pathway and cause global mRNA degradation (Grimm et al 2006), our results indicate that the siRNA pathway is incompatible with the native miRNA pathway in skin cells.”
Myburgh, R., Ivic, S., Pepper, M. S., Gers-Huber, G., Li, D., Audigé, A., Rochat, M.-A., Jaquet, V., Regenass, S., Manz, M. G., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00277-15 · Cited by 42
“miRNAs closely mimic naturally occurring pri-miRNAs and thus are less likely to cause oversaturation of the RNA interference pathway and to affect cellular homeostasis than the widely used shRNAs (42, 43).”
BackgroundKristensen, M. P., Askou, A. L., Aagaard, L., Bruun, G. H., Svalgaard, J. D., Holm‐Nielsen, M. H., Dagnæs‐Hansen, F., Bek, T., Mikkelsen, J. G., Jensen, T. G., et al. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2623 · Cited by 42
Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators
Maepa, M. B., Crowther, C. E., & Arbuthnot, P. B. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2010.533655 · Cited by 43
“Viral vectors that are under development include recombinant adeno-associated viruses (AAVs), lentiviruses and adenoviruses.”
BackgroundInfluentialRotolo, S., Ceccarelli, S., Romano, F., Frati, L., Marchese, C., & Angeloni, A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002528 · Cited by 42
“The optimal concentration for siRNA transfection was experimentally determined to be 5 nM (data not shown), in keeping with recent observations that indicated toxic mechanisms, off-target effects and stimulation of immune response induced by high doses of synthetic RNAi in vitro and in vivo [32].”
BackgroundInnovative Delivery of siRNA to Solid Tumors by Super Carbonate Apatite
Wu, X., Yamamoto, H., Nakanishi, H., Yamamoto, Y., Inoue, A., Tei, M., Hirose, H., Uemura, M., Nishimura, J., Hata, T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116022 · Cited by 42
“demonstrated shRNAmediated liver toxicity due to saturation of the RNAi pathway [48].”
BackgroundsiRNAs: their potential as therapeutic agents – Part I. Designing of siRNAs
Hajeri, P. B., & Singh, S. K. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.06.001 · Cited by 42
Goel, K., & Ploski, J. E. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.914430 · Cited by 42
Yi, Z., Zhao, Y., Yi, Z., Zhang, Y., Tang, G.-B., Zhang, X., Tang, H., Zhang, W., Zhao, Y., Xu, H., et al. (2023) · Genome biology · doi:10.1186/s13059-023-03086-6 · Cited by 42
“…about the safety of LEAPER 2.0 for RNA editing, especially since lethal toxicity was previously observed in animals when using AAV-delivered shRNA, a different RNA modification technique harnessing an endogenous mechanism, due to the saturation of the endogenous small RNA processing pathway [37].”
BackgroundInfluentialIntron-Mediated RNA Interference and microRNA Biogenesis
Ying, S., & Lin, S.-L. (2008) · Methods in molecular biology · doi:10.1007/978-1-60327-547-7_19 · Cited by 46
Progress and Prospects of Anti-HBV Gene Therapy Development
Maepa, M. B., Roelofse, I., Ely, A., & Arbuthnot, P. B. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160817589 · Cited by 45
Wilmott, J. S., Zhang, X. D., Hersey, P., & Scolyer, R. A. (2011) · Pathology · doi:10.1097/pat.0b013e32834a7358 · Cited by 42
“The toxicity is thought to be caused by the saturation of exportin-5 and RISC pathways competing with other critical endogenous microRNAs.(114,115) Mutagenesis has also been observed as a result of microRNA vector insertion.”
BackgroundDesign of siRNA Therapeutics from the Molecular Scale
Angart, P. A., Vocelle, D. B., Chan, C., & Walton, S. P. (2013) · Pharmaceuticals · doi:10.3390/ph6040440 · Cited by 44
“intended target (reducing the activity of the siRNA therapeutic) and that can cause off-target effects (reducing the specificity of the siRNA) [39,40,52].”
BackgroundNeuron‐specific RNA interference using lentiviral vectors
Nielsen, T. T., van Marion, I., Hasholt, L., & Lundberg, C. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1333 · Cited by 42
“Recent reports have suggested that the expression of high levels of shRNA saturates the endogenous RNA machinery, thereby causing disturbances in naturallyoccurring miRNAs, which leads to toxicity and cell death [8,9].”
BackgroundOvercoming obstacles to develop effective and safe siRNA therapeutics
Li, L., & Shen, Y. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902911420 · Cited by 41
“High levels of shRNA expression in hepatocytes using AAV-based gene delivery system have been shown to trigger severe liver toxicity in mice as a result of saturating the endogenous microRNA machinery [55].”
BackgroundMicroRNAs and hepatitis C virus: Toward the end of miR-122 supremacy
Hoffmann, T. W., Duverlie, G., & Bengrine, A. (2012) · Virology Journal · doi:10.1186/1743-422x-9-109 · Cited by 46
“However, these results should be taken with caution as it has also been shown that over-expression of certain pre-miRNA-like molecules in the liver is lethal in mice [15].”
“Skeletal Muscle MicroRNAs: Their Diagnostic and Therapeutic Potential in Human Muscle Diseases”
Alexander, M. S., & Kunkel, L. M. (2015) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-140058 · Cited by 43
“previously shown to induce liver failure due to a saturation of the microRNA/shRNA processing machinery, thus making the virus delivery strategy, dosage, and serotype important in reducing any liver toxicity [96].”
BackgroundTherapeutic application of RNA interference for hepatitis C virus
Watanabe, T., Umehara, T., & Kohara, M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.022 · Cited by 48
MicroRNAs in Cardiovascular Diseases: Biology and Potential Clinical Applications
Kartha, R. V., & Subramanian, S. (2010) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-010-9172-z · Cited by 49
shRNA-induced saturation of the microRNA pathway in the rat brain
van Gestel, M. A., van Erp, S., Sanders, L. E., Brans, M. A. D., Luijendijk, M. C. M., Merkestein, M., Pasterkamp, R. J., & Adan, R. A. H. (2014) · Gene Therapy · doi:10.1038/gt.2013.76 · Cited by 41
Metadata
- Authors
- Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Universitätsklinikum Aachen (DE)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 537-541
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1971643509
- Cited by
- 1,677
- References
- 31
- Citations by year
- 2026: 27 · 2025: 32 · 2024: 49 · 2023: 35 · 2022: 57 · 2021: 36 · 2020: 45 · 2019: 54 · 2018: 54 · 2017: 60 · 2016: 75 · 2015: 94 · 2014: 92 · 2013: 121 · 2012: 121
- FWCI
- 57.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- RNA interference, shRNA, microRNA, XPO5, hepatotoxicity, liver injury, AAV8 vector, siRNA delivery, karyopherins, post-transcriptional gene silencing, mice, gene silencing therapy, dose-dependent toxicity
- MeSH terms
- Animals, Hepatitis B virus, Humans, Liver, Liver Regeneration, Mice, Transgenic, Nucleic Acid Conformation, RNA, Survival Analysis, Karyopherins, RNA Interference, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.